Genentech's Lucentis improves vision in RVO Phase III study
This article was originally published in Scrip
Executive Summary
Genentech's VEGF inhibitor Lucentis (ranibizumab) has been shown to improve the vision of patients with retinal vein occlusion (RVO) in a Phase III study.